• NanoViricides priced a registered direct offering with warrants covering 2,516,339 common shares, matching the common stock sold.
• Each warrant is exercisable at US$ 1.75 per share, expiring 5.5 years from issuance.
• Gross proceeds expected at about US$ 3.8 million; closing targeted around July 27, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-088393), on July 30, 2026, and is solely responsible for the information contained therein.